Daniel Rodrigue, MD
Infectious Disease · Lexington, KYNPI 1386645661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,330 of the $37,455 with a category attached, or 67.6%. Merck accounts for 88.3% of it on its own, with 13 other manufacturers making up the rest. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $196.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$33K
- Gilead$3K
- Insmed, Inc.$504
- Astellas Pharma US Inc$419
- Viiv Healthcare Company$295
- Shionogi Inc$178
- plus $327 from 8 others
What the payments were for
- Consulting fees$1,4704%
- Speaking & faculty fees$25,33068%
- Travel & lodging$6,61018%
- Food & beverage$3,96011%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 51 | $33,065 |
| Gilead | 57 | $2,666 |
| Insmed, Inc. | 23 | $504 |
| Astellas Pharma US Inc | 19 | $419 |
| Viiv Healthcare Company | 16 | $295 |
| Shionogi Inc | 7 | $178 |
| AbbVie(2 entities) | 5 | $96 |
| Pfizer | 4 | $60 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Theratechnologies Inc. | 2 | $46 |
| Cumberland Pharmaceuticals, Inc. | 1 | $26 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $17 |
| Mayne Pharma Commercial LLC | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,455 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TriumeqAbacavir/Dolutegravir/Lamivudi | 43 | $154,124 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $104,252 |
| JulucaDolutegravir/Rilpivirine | 12 | $40,656 |
| TivicayDolutegravir Sodium | 13 | $34,085 |
| Daptomycin | 87 | $21,784 |
| ErtapenemErtapenem Sodium | 31 | $16,336 |
| Meropenem | 24 | $8,950 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $7,954 |
| Vancomycin Hcl | 38 | $7,050 |
| CeftriaxoneCeftriaxone Sodium | 66 | $6,456 |
| Epinephrine | 22 | $4,724 |
| Sodium Chloride0.9 % Sodium Chloride | 44 | $3,790 |
| Cefepime Hcl | 18 | $3,455 |
| Ampicillin Sodium | 11 | $2,364 |
| Doxycycline Monohydrate | 32 | $1,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTriumeq, Juluca, Tivicay | $295 | $228,86568 claims |
| GileadBiktarvy | $2,666 | $104,25218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Lexington
- David DoughertyLexington$145K
- Charles RoseLexington$68K
- Marty AllenLexington$40K
- John MeekLexington$12K
- Mark DoughertyLexington$12K
- Andrea BanksLexington$11K
- Takako SchaningerLexington$8K
- Andrew AlexanderLexington$7K
- Richard GreenbergLexington$6K
- Elizabeth PiercyLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.